Trial Profile
IPI-Biotherapy for Patients With Metastatic Melanoma Previously Treated With Cytotoxic Drugs.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Aldesleukin; Interferon
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Jan 2012 Actual initiation date (Oct 2011) added as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 09 Aug 2011 New trial record